Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells $15,748.32 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 1,526 shares of Precision BioSciences stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $10.32, for a total transaction of $15,748.32. Following the completion of the sale, the chief executive officer now owns 13,772 shares in the company, valued at $142,127.04. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Precision BioSciences Stock Down 3.0 %

Shares of NASDAQ DTIL opened at $10.52 on Monday. The business’s 50 day moving average price is $12.55 and its two-hundred day moving average price is $11.82. The company has a market cap of $72.76 million, a PE ratio of -0.65 and a beta of 1.62. Precision BioSciences, Inc. has a twelve month low of $8.25 and a twelve month high of $27.02.

Precision BioSciences (NASDAQ:DTIL) last posted its earnings results on Wednesday, March 27th. The company reported ($3.35) earnings per share for the quarter, missing analysts’ consensus estimates of $3.00 by ($6.35). Precision BioSciences had a negative return on equity of 204.66% and a negative net margin of 125.84%. The business had revenue of $7.04 million for the quarter, compared to analyst estimates of $28.50 million. As a group, research analysts anticipate that Precision BioSciences, Inc. will post -3.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Precision BioSciences

Several large investors have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its holdings in Precision BioSciences by 8.3% during the 3rd quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares during the last quarter. Tejara Capital Ltd lifted its holdings in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after buying an additional 200,000 shares in the last quarter. Finally, Curi Wealth Management LLC boosted its position in shares of Precision BioSciences by 42.0% in the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock valued at $116,000 after acquiring an additional 100,530 shares during the period. 37.99% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on DTIL shares. Guggenheim began coverage on Precision BioSciences in a report on Tuesday, April 30th. They set a “buy” rating and a $19.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Wednesday, April 17th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.